Last reviewed · How we verify
DFN-11
DFN-11 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by suppressing cAMP degradation in immune cells.
DFN-11 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by suppressing cAMP degradation in immune cells. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | DFN-11 |
|---|---|
| Also known as | Sumatriptan succinate injection |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE4, DFN-11 increases intracellular cAMP levels in inflammatory cells, leading to decreased production of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in respiratory and inflammatory diseases. PDE4 inhibition has been explored for conditions including COPD, asthma, and other inflammatory airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
- Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine (PHASE2)
- DFN-11 Injection in Episodic Migraine With or Without Aura (PHASE3)
- Pilot Study of DFN-11 Injection in Medication Overuse Headache (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFN-11 CI brief — competitive landscape report
- DFN-11 updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI